AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 221 min read$PKBK

PARKE BANCORP, INC. ANNOUNCES CASH DIVIDEND

PARKE BANCORP, INC. (PKBK) filed an SEC Form 8-K — Other Events. Exhibit 99.1 FOR IMMEDIATE RELEASE FOR FURTHER INFORMATION CONTACT : September 22, 2026 Vito S. Pantilione, President and CEO Jonathan D. Hill, Senior Vice President and CFO (856) 256-2500 PARKE BANCORP, INC. ANNOUNCES CASH DIVIDEND WASHINGTON TOWNSHIP, NEW JERSEY – Parke Bancorp

Original reporting
SEC EDGAR 8-K
Published Sep 22, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$PKBK
Bullish
medium confidence
Mentioned
$PKBK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PKBKBullishMed
01

Why it matters

The dividend announcement provides a fresh data point for valuation models and may prompt short‑term buying by dividend‑seeking traders.

02

Market read

A modest dividend declaration for a small regional bank; relevance primarily to income‑focused investors.

03

What to watch

Potential regulatory constraints on future dividends and the bank's capital adequacy could limit sustainability.

Relevance 5/10Novelty 6/10Timing: record date Oct 2 2026

Background

Parke Bancorp is a small community bank listed on NASDAQ Capital Market. The 8‑K filing is the first public disclosure of its quarterly dividend.

Company-level read

Ticker impact

$PKBKBullishMedium confidence
Context

Parke Bancorp announced a $0.20 per share cash dividend payable Oct 16, 2026, with record date Oct 2, 2026.

Expected impact

Potential modest upside or reduced downside risk as dividend‑seeking buyers accumulate shares.

Evidence & confidence

The dividend is modest but signals board confidence; impact is limited given the small amount and the bank's size.

Market effects

Sector

May slightly improve sentiment toward regional community banks as dividend‑paying peers.

Regional

Limited impact on New Jersey banking sector; primarily a company‑specific event.

Global

Low; does not affect broader market indices.

Counterpoint

What could challenge this read

The dividend is small and could be a distraction from underlying earnings pressure.

Key entities

  • company
    Parke Bancorp, Inc.

    Issuer of the dividend.

  • executive
    Vito S. Pantilione

    President and CEO who signed the release.

Read at source← All news

Related articles

OCT 21
$PKBKHigh

PARKE BANCORP, INC. ANNOUNCES THIRD QUARTER 2026 EARNINGS

PARKE BANCORP, INC. (PKBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Parke Bancorp, Inc. 601 Delsea Drive, Washington Township, NJ 08080 Contact: Vito S. Pantilione, President and CEO Jonathan D. Hill, Senior Vice President and CFO (856) 256-2500 PARKE BANCORP, INC. ANNOUNCES THIRD QUARTER 2026 EARNINGS Highlights: Net Income: $12.2 m

SEC EDGAR 8-K2 min
JUL 22
$PKBKMed

PARKE BANCORP, INC. ANNOUNCES SECOND QUARTER 2026 EARNINGS

PARKE BANCORP, INC. (PKBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_970396.htm EXHIBIT 99.1 ex_970396.htm Exhibit 99.1 Parke Bancorp, Inc. 601 Delsea Drive, Washington Township, NJ 08080 Contact: Vito S. Pantilione, President and CEO Jonathan D. Hill, Senior Vice President and CFO (856) 256-2500 PARKE BANCORP, INC. ANNOUNCES SECOND Q

SEC EDGAR 8-K4 min
OCT 21
$ABTHigh

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027

Abbott Laboratories (ABT) plans to spin off its Nutrition division, generating $8.5B in annual revenue, into a separate publicly traded company by the end of 2027. The move, subject to approvals, will allow Abbott to focus on medical devices, diagnostics, and pharmaceuticals, with the new company led by Daniel Salvadori. Existing shareholders will receive shares in both entities, and the transaction is not expected to affect Abbott's 2026 or 2027 financial guidance.

finance.yahoo.com2 min
OCT 21
$ABTMed

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT) shares dropped 4% after announcing plans to spin off its Nutrition business, including Similac, by 2027. The unit generates $8.5B annually but has shown minimal growth. The move leaves Abbott with a medical device and diagnostics business, with $42B in annual sales. The company expects to maintain its 2026 guidance and current dividend payouts. Daniel Salvadori will lead the new nutrition company.

finance.yahoo.com2 min
OCT 21
$UDRHigh

UDR, Apollo form $2B joint venture

UDR and Apollo are forming a $2B joint venture for 19 apartment properties. Apollo will invest $1.34B for a two-thirds stake, while UDR retains one-third and will manage the portfolio. UDR plans to use proceeds for high-growth assets, debt reduction, and corporate purposes. The transaction implies a 6% cap rate and is expected to close on Oct. 29.

finance.yahoo.com2 min
OCT 21
$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

SEC EDGAR 8-K3 min